12 Months-observation of Patients Treated for Hidradenitis Suppurativa, With High Cardiovascular Risk or Established Coronary Plaque: A Prospective Monocentric Study - the HOPE Study
Latest Information Update: 17 Nov 2026
At a glance
- Drugs Secukinumab (Primary)
- Indications Coronary arteriosclerosis; Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 10 Nov 2026 Planned End Date changed from 31 Mar 2027 to 30 Oct 2027.
- 10 Nov 2026 Planned primary completion date changed from 31 Mar 2027 to 30 Oct 2027.
- 10 Nov 2026 Planned initiation date changed from 30 Oct 2026 to 31 Dec 2026.